Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 4/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12378387 | 0.93 | ANO1 (0.41) | GRM2ANO1FFAR1LIPGKEAP1 | |
| SCHEMBL12378386 | 0.92 | LIPG (0.35) | GRM2ANO1FFAR1LIPGKEAP1 | |
| SCHEMBL12378400 | 0.91 | LIPG (0.37) | GRM2ANO1MAOBFFAR1LIPG | |
| SCHEMBL12378378 | 0.91 | SLC2A1 (0.35) | GRM2ANO1FFAR1LIPGKEAP1 | |
| SCHEMBL12378413 | 0.89 | SMN1; SMN2 (0.35) | ANO1 | |
| SCHEMBL12378434 | 0.89 | LIPG (0.35) | GRM2ANO1MAOBFFAR1LIPG | |
| SCHEMBL12378417 | 0.89 | NPC1 (0.37) | ANO1 | |
| SCHEMBL12378388 | 0.89 | KMT2A (0.37) | — | |
| SCHEMBL12378429 | 0.89 | HPGD (0.37) | MAOB | |
| SCHEMBL13624054 | 0.89 | SCN9A (0.38) | GRM2ANO1FFAR1LIPGKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | TYMP, DNTT, PAICS | GRM2 4726/4885ANO1 4694/4885MAOB 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.